Then, we randomly selected 20 patients with stage IV gastric cancer treated with anti-PD-1 therapy in our hospital (all of the patients were pMMR (mismatch repair-proficient), TPS (tumor proportion score) ≥ 5%) for retrospective analysis. This evidence concerns the gene PDCD1 and gastric cancer.